Clinical trials: completed, sponsored by University College, London
Obesity, Diabetes
Semaglutide 2.4 mg in Patients With Poor Weight-loss
A double-blinded, randomised, placebo-controlled trial of semaglutide 3.0 mg/ml in patients with poor weight-loss following bariatric surgery.
- Conditions
- Obesity, Diabetes, Metabolic Syndrome
- Trial name
- BARI-STEP (NCT05073835)
- Testing
- Semaglutide 3 mg
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- University College, London
Waitlist Control, Intervention (Training) Condition
Feasibility and Outcomes of Therapist-led Online Cancer Bereavement Groups
Background: The loss of loved one to cancer brings unique difficulties that impact on the bereavement experience. Mixed support exists for the effectiveness of in-person group interventions for bereaved caregivers, with barriers…
- Trial name
- NCT07002424
- Testing
- Therapeutic - Psychological
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University College, London
Cardiotoxicity, HER2-positive Breast Cancer
Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction
Breast cancer is the most common cancer in the United Kingdom (UK), but improvements in treatment mean 3 in 4 people survive for more than 10 years.
- Conditions
- Cardiotoxicity, HER2-positive Breast Cancer, Heart Failure, Cancer, Therapy-Related
- Trial name
- HER-SAFE (NCT05880160)
- Testing
- Phased withdrawal of heart failure medications
- Where
- 2 sites in United Kingdom
- Volunteers
- 90 people
- Sponsor
- University College, London
Clear Cell Tumor, Gynecologic Cancer
A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer
PEACOCC is a multi-centre, single arm, single stage phase II trial. The overall aim is to determine whether treatment with pembrolizumab is effective in patients with advanced clear cell gynaecological cancer.
- Conditions
- Clear Cell Tumor, Gynecologic Cancer, Advanced Cancer
- Trial name
- PEACOCC (NCT03425565)
- Testing
- Pembrolizumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- University College, London
Stroke, Subarachnoid Hemorrhage
MUSic Therapy In Complex Specialist Neurorehabilitation
Aim: Investigate whether patients undergoing specialist rehabilitation after complex neurological injury show different functional outcomes if music therapy is included in their rehabilitation program compared to usual care.
- Conditions
- Stroke, Subarachnoid Hemorrhage, Traumatic Brain Injury, Tumor, Brain
- Trial name
- MUSICS (NCT05777499)
- Testing
- Music Therapy, Control Therapy
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- University College, London
Post-transplant Lymphoproliferative Disease, Transplant-Related Hematologic Malignancy
Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant
This is an open label, non-randomised, multicentre Phase I to determine the safety of tacrolimus-resistant autologous EBV-specific cytotoxic T-cells (EBV CTL) and compare their expansion/persistence with control EBV CTL in solid…
- Trial name
- ITREC (NCT03131934)
- Testing
- Autologous EBV-CTL transduced with vector SFG-CNA12, Autologous EBV-CTL transduced with control vector SFG-CNA8, Leucapheresis
- Where
- 2 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- University College, London
Cancer Survivors, Cardiotoxicity
In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors
The BREATHS trial aims to investigate whether overnight in-bedroom air filtration reduces inflammation and cardiac biomarkers in adult survivors of cancer who are at high risk for cardiovascular complications.
- Conditions
- Cancer Survivors, Cardiotoxicity, Cardiovascular Toxicity Induced by Antitumoral Drugs
- Trial name
- BREATHS (NCT06778122)
- Testing
- High efficiency particulate air filtration system (nightly administration), High efficiency particulate air filtration system (nightly and daily administration)
- Where
- 3 sites in Spain
- Volunteers
- 10 people
- Sponsor
- University College, London
Anxiety, Depression
Evaluating Knowledge Insight Tools (KIT) for Reducing Anxiety and Low Mood in UK Secondary School Students
Background and Study Aims: Secondary school students are reporting unprecedented levels of anxiety and mood difficulties. To ensure that the needs of all young people are met, there is a need to evaluate more accessible forms of…
- Conditions
- Anxiety, Depression, Internalizing Problems, Low Mood
- Trial name
- NCT06188962
- Testing
- CBT-informed school-based counselling
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- University College, London
Head and Neck Cancer
Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer
The phase I trial aims to determine the recommended phase II dose (RP2D) and schedule of olaparib in combination with standard cisplatin-based chemoradiotherapy, in patients with high-risk locally advanced squamous cell carcinoma…
- Trial name
- ORCA-2 (NCT02308072)
- Testing
- Olaparib, Cisplatin, IMRT
- Where
- 3 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- University College, London
Antiphospholipid Syndrome, Systemic Lupus Erythematosus
RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome
Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomised, controlled, open-label, phase IIb, non-inferiority proof of principle trial.
- Conditions
- Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Stroke, Ischemic Stroke
- Trial name
- RISAPS (NCT03684564)
- Testing
- Rivaroxaban, Warfarin
- Where
- 6 sites in United Kingdom
- Volunteers
- 43 people
- Sponsor
- University College, London
Head and Neck Cancer, Squamous Cell Carcinoma
EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer
Head \& neck (H\&N) cancer is the eighth most common cancer in the UK. Advanced H\&N cancer which has come back after treatment or has spread to other parts of the body is incurable and the average life expectancy of these…
- Trial name
- EACH (NCT03494322)
- Testing
- Avelumab, Cetuximab
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- University College, London
Ovarian Cancer, Fallopian Tube Cancer
Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer
The overall aim of the study is to demonstrate a clinically meaningful extension of progression free survival using maintenance pembrolizumab.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- PROMPT (NCT03430700)
- Testing
- Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- University College, London
Bladder Cancer
Trial to Compare Robotically Assisted Radical Cystectomy With Open Radical Cystectomy
This is a prospective multicentre randomised controlled trial comparing the outcomes from Intracorporeal RARC (iRARC) with open radical cystectomy (ORC) in patients with bladder cancer.
- Trial name
- iROC (NCT03049410)
- Testing
- Intracorporeal Robot Assisted Radical Cystectomy, Open Radical Cystectomy
- Where
- 8 sites in United Kingdom
- Volunteers
- 339 people
- Sponsor
- University College, London
Menopause
Group Compassionate Mind Training for Adults Experiencing the Menopause Transition
Menopause transition occurs naturally for women aged 45-55. In addition to the hormone changes, there are often changes in other areas of life including low mood, anxiety, 'brain fog' and embarrassment.
- Trial name
- NCT06462157
- Testing
- Compassionate Mind Training
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University College, London
Parkinson's Disease
Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease
This study is a clinical trial in patients with Parkinson's disease (PD), of a drug called exenatide, which is already licensed for the treatment of patients with type 2 diabetes.
- Trial name
- Exenatide-PD3 (NCT04232969)
- Testing
- Exenatide extended release 2mg (Bydureon)
- Where
- United Kingdom
- Volunteers
- 194 people
- Sponsor
- University College, London
Posttraumatic Stress Disorder (PTSD), Insomnia
Yoga Nidra for Insomnia and Posttraumatic Stress Symptoms
This randomized feasibility study is designed to investigate the feasibility of recruitment and delivery of two variations (brief; full) of a virtual Integrative Restoration (iRest) yoga nidra meditation intervention in stressor…
- Conditions
- Posttraumatic Stress Disorder (PTSD), Insomnia, Stressor, Psychological, Psychological Trauma
- Trial name
- NCT06888336
- Testing
- Yoga nidra (full), Yoga nidra (brief)
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University College, London
Non-small Cell Lung Cancer
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity
DARWIN II is a multi-arm non-randomised phase II trial, Eligible patient will be those who relapse with NSCLC (clinical trials.gov ref. NCT02183883). .
- Trial name
- DARWINII (NCT02314481)
- Testing
- MPDL3280A, Vemurafenib, Alectinib
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Parkinson's Disease (PD)
Mental Health Support for People Affected by Parkinson's
In addition to increasingly severe physical symptoms, Parkinson's can cause distressing mental health issues. These include anxiety, depression, and memory and thinking problems, caused by a combination of biological and…
- Trial name
- NCT06992869
- Testing
- Group-based psychological therapy
- Where
- United Kingdom
- Volunteers
- 138 people
- Sponsor
- University College, London
Diffuse Large B Cell Lymphoma
Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy
The purpose of this trial is to compare the efficacy and safety of Inotuzumab Ozogamicin in combination with R-CVP with that of R-G-CVP for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) in a population of patients not…
- Trial name
- INCA (NCT01679119)
- Testing
- Cyclophosphamide, Vincristine, Prednisolone
- Where
- 40 sites in United Kingdom
- Volunteers
- 129 people
- Sponsor
- University College, London
Chronic Lung Disease of Prematurity, Respiratory Distress Syndrome in Premature Infant
Recombinant Surfactant Protein D (rfhSP-D) to Prevent Neonatal Chronic Lung Disease
The purpose of this study is to identify the safest dose of recombinant surfactant protein D (drug name: rfhSP-D) that can be administered to preterm infants born at less than 30 weeks gestation, and to help identify whether this…
- Conditions
- Chronic Lung Disease of Prematurity, Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
- Trial name
- RESPONSE (NCT05898633)
- Testing
- Recombinant fragment of human surfactant protein D (rfhSP-D)
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- University College, London